Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 10/20 | 0.45 |
| ▸ | ESR1 | P03372 | 9/20 | 0.45 |
| ▸ | MIF | P14174 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | ESRRB | O95718 | 4/20 | 0.39 |
| ▸ | ESRRA | P11474 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12254998 | 0.83 | ESR2 (0.47) | ESR2ESR1MIFMAOAMAOB | |
| SCHEMBL6208215 | 0.79 | ESR2 (0.58) | ESR2ESR1MIFMAOAMAOB | |
| SCHEMBL2566862 | 0.78 | ESR2 (0.45) | ESR2ESR1MIF | |
| SCHEMBL8934596 | 0.77 | ESR1 (0.58) | ESR2ESR1MIF | |
| SCHEMBL2564011 | 0.77 | ESR1 (0.58) | ESR2ESR1MIF | |
| SCHEMBL2567309 | 0.76 | ESR1 (0.59) | ESR2ESR1 | |
| SCHEMBL17861951 | 0.73 | ESRRB (0.49) | ESR2ESR1MIFMAOAMAOB | |
| SCHEMBL243923 | 0.73 | ESR1 (0.54) | ESR2ESR1MAOBESRRBESRRA | |
| SCHEMBL2180565 | 0.73 | ESR2 (0.47) | ESR2ESR1MIF | |
| SCHEMBL13090322 | 0.72 | ALOX12 (0.44) | ESR2ESR1MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367659-B2 | Oxazinyl isoflavonoid compounds, medicaments and use | MARSHALL EDWARDS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-2125831-B1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | NOVOGEN RES PTY LTD (AU) | 2011-12-28 | — | — | EP | disclosed |
| US-20110046722-A1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | NOVOGEN RESEARCH PTY LTD (AU) | 2011-02-24 | — | — | US | disclosed |
| WO-2008106715-A1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | NOVOGEN RESEARCH PTY LTD (AU) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046722-A1 | OXAZINYL ISOFLAVONOID COMPOUNDS, MEDICAMENTS AND USE | TNNI3, NFE2L2, OAT | ESR2 85/4885ESR1 138/4885MIF 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.